Posted by Michael Wonder on 22 Jan 2019
PHARMAC publishes PTAC outcome for nivolumab in renal cell carcinoma
22 January 2019 - The Committee reviewed the application for nivolumab for the second-line treatment of relapsed clear cell renal cell carcinoma following prior angiogenic therapy.
The Committee recommended that nivolumab be funded with a low priority for the second- line treatment of relapsed clear cell renal cell carcinoma following prior angiogenic therapy subject to Special Authority criteria in line with published evidence and to be determined based on further advice from the Cancer Treatment Subcommittee of PTAC (CaTSoP).
